CA2522275A1 - Rage antagonists as agents to reverse amyloidosis and diseases associated therewith - Google Patents

Rage antagonists as agents to reverse amyloidosis and diseases associated therewith Download PDF

Info

Publication number
CA2522275A1
CA2522275A1 CA002522275A CA2522275A CA2522275A1 CA 2522275 A1 CA2522275 A1 CA 2522275A1 CA 002522275 A CA002522275 A CA 002522275A CA 2522275 A CA2522275 A CA 2522275A CA 2522275 A1 CA2522275 A1 CA 2522275A1
Authority
CA
Canada
Prior art keywords
alkylene
aryl
alkyl
fused
alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002522275A
Other languages
English (en)
French (fr)
Inventor
Adnan M. M. Mjalli
Robert C. Andrews
Jane M. Shen
Robert Rothlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2522275A1 publication Critical patent/CA2522275A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002522275A 2003-05-20 2004-05-20 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith Abandoned CA2522275A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47196903P 2003-05-20 2003-05-20
US60/471,969 2003-05-20
PCT/US2004/016104 WO2005000295A1 (en) 2003-05-20 2004-05-20 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith

Publications (1)

Publication Number Publication Date
CA2522275A1 true CA2522275A1 (en) 2005-01-06

Family

ID=33551437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002522275A Abandoned CA2522275A1 (en) 2003-05-20 2004-05-20 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith

Country Status (10)

Country Link
US (2) US20050026811A1 (https=)
EP (1) EP1635823A1 (https=)
JP (1) JP2007503469A (https=)
CN (1) CN1805743A (https=)
AU (1) AU2004251599A1 (https=)
BR (1) BRPI0410436A (https=)
CA (1) CA2522275A1 (https=)
MX (1) MXPA05012350A (https=)
WO (1) WO2005000295A1 (https=)
ZA (1) ZA200508300B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749537B1 (en) * 1995-12-14 2004-06-15 Hickman Paul L Method and apparatus for remote interactive exercise and health equipment
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US7423177B2 (en) 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1235583C (zh) * 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006036922A2 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
BRPI0612287A8 (pt) * 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
CA2685540C (en) * 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
US20100167646A1 (en) * 2008-12-30 2010-07-01 Motorola, Inc. Method and apparatus for device pairing
US20100167711A1 (en) * 2008-12-30 2010-07-01 Motorola, Inc. Method and system for creating communication groups
US20100278835A1 (en) * 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
WO2011103091A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
US9339691B2 (en) 2012-01-05 2016-05-17 Icon Health & Fitness, Inc. System and method for controlling an exercise device
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
NZ705813A (en) * 2012-10-05 2018-02-23 Vtv Therapeutics Llc Treatment of mild and moderate alzheimer’s disease
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
US9254409B2 (en) 2013-03-14 2016-02-09 Icon Health & Fitness, Inc. Strength training apparatus with flywheel and related methods
EP3623020B1 (en) 2013-12-26 2024-05-01 iFIT Inc. Magnetic resistance mechanism in a cable machine
WO2015138339A1 (en) 2014-03-10 2015-09-17 Icon Health & Fitness, Inc. Pressure sensor to quantify work
US10426989B2 (en) 2014-06-09 2019-10-01 Icon Health & Fitness, Inc. Cable system incorporated into a treadmill
WO2015195965A1 (en) 2014-06-20 2015-12-23 Icon Health & Fitness, Inc. Post workout massage device
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US10391361B2 (en) 2015-02-27 2019-08-27 Icon Health & Fitness, Inc. Simulating real-world terrain on an exercise device
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
AU2017225537B2 (en) 2016-03-01 2020-07-30 Vtv Therapeutics Llc Piperidine derivative and methods of use thereof
US10493349B2 (en) 2016-03-18 2019-12-03 Icon Health & Fitness, Inc. Display on exercise device
US10272317B2 (en) 2016-03-18 2019-04-30 Icon Health & Fitness, Inc. Lighted pace feature in a treadmill
US10625137B2 (en) 2016-03-18 2020-04-21 Icon Health & Fitness, Inc. Coordinated displays in an exercise device
CN108349903B (zh) * 2016-09-27 2021-07-13 杭州领业医药科技有限公司 Ttp488加成盐及其晶型、制备方法及药物组合物
US10671705B2 (en) 2016-09-28 2020-06-02 Icon Health & Fitness, Inc. Customizing recipe recommendations
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
CN115594642B (zh) * 2021-06-28 2024-12-27 广西医科大学 阿齐瑞格三氮唑衍生物及其抗乳腺癌用途
CN118615283A (zh) * 2024-05-31 2024-09-10 中南大学湘雅三医院 Ttp488在制备抑制淋巴细胞耗竭的药物中的应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3255202A (en) * 1963-08-23 1966-06-07 Union Carbide Corp Process for the preparation of 2-(acylamidoalkyl)benzimidazoles
NL7017486A (https=) * 1969-12-15 1971-06-17
US3708598A (en) * 1970-07-10 1973-01-02 Sandoz Ag Substituted 2,4-(omega-aminoalkoxy)phenyl imidazoles as cholesterol reducing agents
US4024271A (en) * 1971-03-09 1977-05-17 Smith Kline & French Laboratories Limited Pharmacologically active guanidine compounds
FR2257269B1 (https=) * 1973-10-03 1978-12-29 Delalande Sa
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) * 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5585344A (en) * 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US5358960A (en) * 1984-03-19 1994-10-25 The Rockefeller University Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles
US5202424A (en) * 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4873313A (en) * 1985-01-18 1989-10-10 Beckman Research Institute Of City Of Hope Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens
US4963539A (en) * 1987-09-10 1990-10-16 E. R. Squibb & Sons, Inc. Phosphonate and phosphonamide endopeptidase inhibitors
DE3815234A1 (de) * 1988-05-05 1989-11-16 Sueddeutsche Kalkstickstoff Beschleuniger fuer cyanamid enthaltende epoxidhaerter
EP0352581A3 (de) * 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5166214A (en) * 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5318984A (en) * 1988-12-05 1994-06-07 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
CA2085844A1 (en) * 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
DE4222980A1 (de) * 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5523317A (en) * 1993-07-05 1996-06-04 Nippon Chemiphar Co., Ltd. Method of reducing blood pressure
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5939526A (en) * 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5688653A (en) * 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US5922770A (en) * 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6416733B1 (en) * 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US6100098A (en) * 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
US6197791B1 (en) * 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US5817823A (en) * 1997-04-17 1998-10-06 Sepracor Inc. Method for synthesizing 2-substituted imidazoles
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
CA2318778A1 (en) * 1998-02-25 1999-09-02 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
WO1999048489A2 (en) * 1998-03-25 1999-09-30 South Alabama Medical Science Foundation Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
DK1083889T3 (da) * 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
FR2780404B1 (fr) * 1998-06-26 2001-04-13 Adir Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
NZ511674A (en) * 1998-12-23 2003-11-28 Du Pont Pharm Co Nitrogen containing heterobicycles as factor Xa inhibitors
ES2260033T3 (es) * 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
IT1313601B1 (it) * 1999-08-05 2002-09-09 Isagro Ricerca Srl Fenilpirazoli ad attivita' erbicida
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US7423177B2 (en) * 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
IL153246A0 (en) * 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2002000648A1 (en) * 2000-06-28 2002-01-03 Ssp Co., Ltd. Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
US6541639B2 (en) * 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
AU2002213477A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Process for preparation of n-substituted 2-sulfanylimidazoles
US6441064B1 (en) * 2000-11-01 2002-08-27 Air Products And Chemicals, Inc. Imidazole-phosphoric acid salts as accelerators for dicyandiamide in one-component epoxy compositions
CN1235583C (zh) * 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7077873B2 (en) * 2002-09-10 2006-07-18 L'Oréal, SA Composition for the dyeing of human keratinous fibres comprising a monocationic monoazo dye
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith

Also Published As

Publication number Publication date
AU2004251599A1 (en) 2005-01-06
ZA200508300B (en) 2007-03-28
US20050026811A1 (en) 2005-02-03
MXPA05012350A (es) 2006-05-25
BRPI0410436A (pt) 2006-05-30
EP1635823A1 (en) 2006-03-22
WO2005000295A1 (en) 2005-01-06
US20090035302A1 (en) 2009-02-05
JP2007503469A (ja) 2007-02-22
CN1805743A (zh) 2006-07-19

Similar Documents

Publication Publication Date Title
CA2522275A1 (en) Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
JP6672500B2 (ja) 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
CA2440037C (en) Benzimidazole derivatives for modulating the rage receptor
RS60679B1 (sr) Neurozaštitna biciklična jedinjenja i postupci za njihovu upotrebu u lečenju poremećaja iz spektra autizma i neurorazvojnih poremećaja
US20030186946A1 (en) Suppression of cytotoxic protein conformers
JP7702883B2 (ja) 神経変性疾患、好ましくはアルツハイマー病を治療するための２－フェニル－６－（１ｈ－イミダゾール－１－イル）キナゾリンの使用
JP2015536965A (ja) １−［１−（ベンゾイル）−ピロリジン−２−カルボニル］−ピロリジン−２−カルボニトリル誘導体
US6992064B2 (en) N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing such trimeres
US6174910B1 (en) AT1 receptor antagonist for the stimulation of apoptosis
US20230144901A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
US20200360366A1 (en) Prolylhydroxylase/atf4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
JP5597339B2 (ja) オキシカム化合物の使用
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
US12589090B2 (en) Compounds and methods for the treatment of degenerative disorders
RS66215B1 (sr) 1-[1-(4-benziloksi-3,5-difluoro-benzoil)-4-fluoro-pirolidin-2-karbonil]-pirolidin-2-karbonitril
HK1212603B (zh) 治療阿爾茨海默病及相關疾病的組合療法
WO2010142642A1 (en) 4 -hydrazono- 1,4 -dihydropyridine derivatives for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead